X-74524723-C-T
Variant summary
Our verdict is Pathogenic. Variant got 20 ACMG points: 20P and 0B. PVS1PM2PP3_ModeratePP5_Very_Strong
The NM_006517.5(SLC16A2):c.940C>T(p.Arg314*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_006517.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 20 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC16A2 | ENST00000587091.6 | c.940C>T | p.Arg314* | stop_gained | Exon 3 of 6 | 1 | NM_006517.5 | ENSP00000465734.1 | ||
SLC16A2 | ENST00000590447.1 | c.379C>T | p.Arg127* | stop_gained | Exon 2 of 4 | 5 | ENSP00000466213.1 | |||
SLC16A2 | ENST00000636771.1 | n.*641C>T | non_coding_transcript_exon_variant | Exon 4 of 7 | 5 | ENSP00000490445.1 | ||||
SLC16A2 | ENST00000636771.1 | n.*641C>T | 3_prime_UTR_variant | Exon 4 of 7 | 5 | ENSP00000490445.1 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Allan-Herndon-Dudley syndrome Pathogenic:2
Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant (PVS1_VS). It is not observed in the gnomAD v2.1.1 dataset (PM2). The variant has been reported as pathogenic (ClinVar ID: VCV000212186.1). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. -
- -
Spastic paraplegia Pathogenic:1
This sequence change creates a premature translational stop signal (p.Arg314*) in the SLC16A2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC16A2 are known to be pathogenic (PMID: 20083155, 25527620). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with MCT8 deficiency (PMID: 32559475). This variant is also known as p.R388X. ClinVar contains an entry for this variant (Variation ID: 212186). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:1
The R314X variant in the SLC16A2 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The R314X variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. Protein truncating pathogenic variants downstream of this variant have been reported in the Human Gene Mutation Database in association with Allan-Herndon-Dudley syndrome (Stenson et al., 2014), supporting the pathogenicity of more upstream truncating variants. We interpret R314X as a pathogenic variant. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at